Search

Your search keyword '"Rebecca, Aft"' showing total 3 results
Start Over Author "Rebecca, Aft" Publisher harborside press, llc
3 results on '"Rebecca, Aft"'

1. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Author

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen Chew, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer Burns, and Rashmi Kumar

Subjects
Carcinoma, Intraductal, Noninfiltrating, Oncology, Humans, Breast Neoplasms, Female, Medical Oncology
Abstract

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visitNCCN.org.

Published
2022
Full Text
View/download PDF

2. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Author

Joanne E. Mortimer, Mary Lou Smith, Rashmi Kumar, Karen L. Smith, Jame Abraham, Harold J. Burstein, Chau T. Dang, Doreen M. Agnese, Sharon H. Giordano, Lori J. Goldstein, Sara H. Javid, Sarah L. Blair, Jessica Young, Marilyn Leitch, Ingrid A. Mayer, Lori J. Pierce, Janice A. Lyons, Jairam Krishnamurthy, Kari B. Wisinski, John H. Ward, William J. Gradishar, Jennifer M. Matro, Matthew P. Goetz, Sameer A. Patel, Meena S. Moran, Erica Stringer-Reasor, Steven J. Isakoff, Ruth O'Regan, Jennifer L. Burns, Rebecca Aft, Hope S. Rugo, Melinda L. Telli, Anthony D. Elias, Rachel C. Jankowitz, Amy M. Sitapati, Kimberly H. Allison, Hatem Soliman, and Sara A. Hurvitz

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Carcinoma in situ, Phyllodes tumor, medicine.disease, Inflammatory breast cancer, Systemic therapy, Patient advocacy, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Surgical oncology, 030220 oncology & carcinogenesis, Internal medicine, Male breast cancer, medicine, skin and connective tissue diseases, business
Abstract

The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor–positive, HER2-negative breast cancer.

Published
2021
Full Text
View/download PDF

3. Breast Cancer, Version 3.2018

Author

Amy M. Sitapati, Kimberly H. Allison, Jessica Young, Joanne E. Mortimer, William B. Farrar, Benjamin O. Anderson, Ruth O'Regan, Karen L. Smith, Mary Lou Smith, Janice A. Lyons, William J. Gradishar, Lori J. Goldstein, Elizabeth C. Reed, Rashmi Kumar, Chau T. Dang, Hatem Soliman, Rebecca Aft, Jame Abraham, Lori J. Pierce, Matthew P. Goetz, Harold J. Burstein, Hope S. Rugo, Sameer A. Patel, Sharon H. Giordano, Melinda L. Telli, Steven J. Isakoff, John H. Ward, Meena S. Moran, Sarah L. Blair, Ingrid A. Mayer, Anthony D. Elias, P. Kelly Marcom, and Dorothy A. Shead

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Systemic chemotherapy, business.industry, medicine.medical_treatment, MEDLINE, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, Adjuvant
Abstract

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results